Anixa Biosciences Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Anixa Biosciences Inc 's ROA in the third quarter of 2026?
Anixa Biosciences Inc recorded a cumulative net loss of $-10 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -56.16%.

However, within the Healthcare sector 652 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jul 31 2026 quarter, so far to 4054, from total ROA ranking in the second quarter of 2026 at 4723.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jul 31 2026) III. Quarter	(Apr 30 2026) II. Quarter	(Jan 31 2026) I. Quarter	(Oct 31 2025) IV. Quarter	(Jul 31 2025) III. Quarter
Y / Y Total Assets Change	56.03 %	-12.44 %	-25.52 %	-72.9 %	-22.95 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-10	-10	-10	-11	-11
Return On Assets (TTM)	-56.16 %	-62.61 %	-62.29 %	-61.01 %	-38.83 %
ANIX's Total Ranking	# 4054	# 4723	# 4134	# 4155	# 4258
Total Assets (TTM) in million	28	15	16	16	18
Seq. Total Assets Change	85.27 %	-7.56 %	0 %	-8.9 %	3.97 %
Seq. Net Income Change	-	-	-	-	-

ANIX's 5 Years Annual ROA >> Back to ANIX Management Effectiveness >> Compare ANIX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 299
Sector	# 653
Overall	# 4063

Return On Assets Statistics
High	Average	Low
-11.51 %	-86.71 %	-265.08 %
(Apr 30 2015)		(Apr 30 2019)

Financial Statements
Anixa Biosciences Inc 's Assets	$ 28 million	ANIX's Balance sheet
Anixa Biosciences Inc 's Income	$ -3 million	Quarterly ANIX's Income Statement
ANIX's Income by Division		See ANIX's Income by Division

Annual Return On Assets	(Oct 31 2025) FY 2025	(Oct 31 2024) FY 2024	(Oct 31 2023) FY 2023	(Oct 31 2022) FY 2022	(Oct 31 2020) FY 2020
Y / Y Total Assets Change	-25.52 %	-99.94 %	113507.41 %	221.72 %	50.2 %
Total Assets in million	16	22	34,550	30	9
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-11	-13	-10	-14	-10
Annual Return On Assets	-68.58 %	-58.81 %	-0.03 %	-45.28 %	-106.76 %

ANIX's 5 Years Annual ROA >> Back to ANIX Management Effectiveness >> Compare ANIX ROA to its Competitors

More Return On Assets Ratios
ANIX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ANIX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ANIX's Competitors
Subscribers only: Roa for Anixa Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for ANIX's Customers

You may also want to know
ANIX's Roi	ANIX's Inventory Turnover Ratio	ANIX's Growth Rates	ANIX's Dividend Comparisons
	ANIX's Profitability Ratios	ANIX's Asset Turnover Ratio	ANIX's Dividend Growth
ANIX's Roe	ANIX's Valuation Ratios	ANIX's Financial Strength Ratios	ANIX's Dividend Payout Ratio

Companies with similar Return On Assets at Jul 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-17T09:30:54+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.